Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations

References

• Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24. doi:10.1038/s41572-020-0158-0
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38–44. doi:10.1136/bjophthalmol-2016-309034
   PubMed Web of Science ®Google Scholar
• Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370–1380. doi:10.1093/annonc/mdz176
   PubMed Web of Science ®Google Scholar
• Lane AM, Kim IK, Gragoudas ES. Long-term risk of melanoma-related mortality for patients with uveal melanoma treated with proton beam therapy. JAMA Ophthalmol. 2015;133(7):792–796. doi:10.1001/jamaophthalmol.2015.0887
   PubMed Web of Science ®Google Scholar
• Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–4659. doi:10.1167/iovs.03-0538
   PubMed Web of Science ®Google Scholar
• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–1678. doi:10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g
   PubMed Web of Science ®Google Scholar
• Chacón M, Pfluger Y, Angel M, Waisberg F, Enrico D. Uncommon subtypes of malignant melanomas: a review based on clinical and molecular perspectives. Cancers. 2020;12(9):2362. doi:10.3390/cancers12092362
   PubMed Web of Science ®Google Scholar
• Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39(6):599–607. doi:10.1200/jco.20.00605
   PubMed Web of Science ®Google Scholar
• Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586–598. doi:10.1200/jco.20.00550
   PubMed Web of Science ®Google Scholar
• Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204–220.e15. doi:10.1016/j.ccell.2017.07.003
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase iii, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36(12):1232–1239. doi:10.1200/jco.2017.74.1090
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311(23):2397–2405. doi:10.1001/jama.2014.6096
   PubMed Web of Science ®Google Scholar
• Nathan P, Needham A, Corrie PG, et al. LBA73 - SELPAC: a 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Ann Oncol. 2019;30:v908–v910. doi:10.1093/annonc/mdz394.070
   PubMed Web of Science ®Google Scholar
• FDA, Resources for information on approved drugs. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma. Accessed September 01, 2022.
   Google Scholar
• Boudousquie C, Bossi G, Hurst JM, Rygiel KA, Jakobsen BK, Hassan NJ. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells. Immunology. 2017;152(3):425–438. doi:10.1111/imm.12779
   PubMed Web of Science ®Google Scholar
• Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: why, what, how, and which. Mol Immunol. 2015;67(2Pt A):67–74. doi:10.1016/j.molimm.2015.01.024
   PubMedGoogle Scholar
• Crabb JW, Hu B, Crabb JS, et al. iTRAQ quantitative proteomic comparison of metastatic and non-metastatic uveal melanoma tumors. PLoS One. 2015;10(8):e0135543. doi:10.1371/journal.pone.0135543
   PubMed Web of Science ®Google Scholar
• Harper J, Adams KJ, Bossi G, et al. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS One. 2018;13(10):e0205491. doi:10.1371/journal.pone.0205491
   PubMed Web of Science ®Google Scholar
• Middleton MR, Steven NM, Evans TJ, et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: results from the FIH study in melanoma. J Clin Oncol. 2016;34(15_suppl):3016. doi:10.1200/JCO.2016.34.15_suppl.3016
   Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729
   PubMed Web of Science ®Google Scholar
• Sacco J, Carvajal R, Butler M, et al. 64MO - a phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). Ann Oncol. 2020;31:S1441–S1451. doi:10.1016/j.annonc.2020.10.552
   Google Scholar
• Shoushtari A, Collins L, Espinosa E, et al. Early reduction in ctDNA, regardless of best RECIST response, is associated with overall sur vival on tebentafusp in previously treated metastatic uveal noma patients. Ann Oncol. 2021;32(Suppl 5). doi:10.1016/j.annonc.2021.08.1702
   Google Scholar
• Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–1206. doi:10.1056/NEJMoa2103485
   PubMed Web of Science ®Google Scholar
• Hurley CK, Kempenich J, Wadsworth K, et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. Hla. 2020;95(6):516–531. doi:10.1111/tan.13811
   PubMed Web of Science ®Google Scholar
• Ikeguchi A, Sacco JJ, Luke JJ, et al. Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a Phase 3 trial of metastatic uveal melanoma. J Clin Oncol. 2022;40(16_suppl):9584. doi:10.1200/JCO.2022.40.16_suppl.9584
   Google Scholar
• Hassel JC, Rutkowski P, Baurain J-F, et al. Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma. J Clin Oncol. 2021;39(15_suppl):9527. doi:10.1200/JCO.2021.39.15_suppl.9527
   Google Scholar
• Sullivan RJ, Milhem MM, Demidov LV, et al. Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM). J Clin Oncol. 2022;40(16_suppl):9585. doi:10.1200/JCO.2022.40.16_suppl.9585
   Web of Science ®Google Scholar
• Hamid OST, Davar D, Davar D, et al. Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Ann Oncol. 2022;33(suppl_7):S331–S355. doi:10.1016/annonc/annonc1058
   Web of Science ®Google Scholar